Drug intelligence / Profile preview

isomaltooligosaccharide gynecological gel

Development stage: Unknown
Lead developer: Sichuan Provincial Maternal and Child Health Hospital
Modality: Small Molecules
Administration: Vaginal

Overview

Isomaltooligosaccharide gynecological gel is a prebiotic formulation designed for vaginal administration to modulate the vaginal microbiota. It is currently being evaluated in clinical trials, specifically for women with polycystic ovary syndrome (PCOS) undergoing frozen embryo transfer (FET). The gel's mechanism of action involves selectively promoting the growth of beneficial vaginal bacteria, such as Lactobacillus species, to create a more favorable environment for embryo implantation and improve clinical pregnancy rates. The development is led by the Sichuan Provincial Women’s and Children’s Hospital.

Other names: isomaltooligosaccharide vaginal gel

Beyond the preview

Go deeper on isomaltooligosaccharide gynecological gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isomaltooligosaccharide gynecological gel.

Explore the full profile